Schalast advised Meliodays Medical GmbH on its pre-seed financing round of over EUR 800,000

A Schalast team, led by VC Partner Dr. Marc-André Rousseau, advised the pharmaceutical start-up Meliodays Medical GmbH on its oversubscribed pre-seed financing round of over EUR 800,000. It was led by capacura GmbH, with participation of FS Life Science Investment GmbH as well as other early-stage investors and business angels specializing in the healthcare market. Meliodays Medical GmbH is a young pharmaceutical company focusing on the development of a new therapy for the hormone-free and locally effective treatment of menstrual pain.  

With the capital from the successful completion of its first financing round, Meliodays Medical will advance the development of MelioOne, a novel, hormone-free, locally acting treatment for menstrual pain, and finalize preparations for preclinical testing of its innovative intrauterine application. By using a proven polymer technology, a very small amount of pain medication is released directly into the uterus, effectively treating period pain and avoiding systemic side effects. In the future, Meliodays Medical's innovative technology could also be used in the treatment of endometriosis. The company has already secured patent rights for MelioOne in over 150 countries. 

Simone Sabbione, co-founder and CEO of Meliodays Medical, explained: “We are delighted to have attracted such experienced healthcare and impact investors for our first financing round and warmly welcome them to the Meliodays shareholder group. Their investment and the strong interest in our significantly oversubscribed pre-seed round show that period pain is now recognized as a significant health burden affecting large portions of the global population. Now, we can finally work on urgently needed innovative solutions.”